Table 1. Baseline characteristics of the study population with 48 patients with essential thrombocythemia (ET) and 48 patients with coronary artery disease (CAD).
| ET patients | CAD patients | Reference interval | |
|---|---|---|---|
| Demographics | |||
| Age, y | 64.5 (52.0–72.0) | 63.0 (54.0–68.0) | |
| Male sex, n (%) | 20 (41.7) | 40 (83.3) | |
| Current smokers, n (%) | 4 (8.3) | 13 (27.1) | |
| Body mass index, kg m −2 | 24.2 (21.4–26.8) | 27.7 (25.1–28.7) | 18.5–25.0 a |
| Previously thromboembolic complications, n (%) | 5 (10.4) | 48 (100) | |
| Mutation status | |||
| JAK2 mutation, n (%) | 32 (66.7) | ||
| CALR mutation, n (%) | 12 (25.0) | ||
| MPL mutation or triple negative, n (%) | 4 (8.3) | ||
| Time from diagnosis, y | 6.1 | ||
| Biochemistry | |||
| Hemoglobin, mmol/L | 8.6 (8.1–9.0) | 9.2 (8.7–9,5) | 7.3–10.5 b |
| Leucocyte count, × 10 9 /L | 6.0 (4.9–9.0) | 6.3 (5.2–7.8) | 3.5–10.0 |
| Platelet count, × 10 9 /L | 512.5 (393.8–623.5) | 230.5 (196.3–282.8) | 145–400 b |
| Mean platelet volume, fL | 9.8 (9.1–10.5) | 10.8 (10.3–11.5) | 6.5–12.0 b |
| Platelet large cell ratio, % | 23.1 (18.7–29.4) | 30.9 (27.3–37.8) | 11.9–66.9 |
| Platelet distribution width, fL | 10.9 (9.8–12.8) | 13.0 (11.8–15.0) | 9.9–16.1 b |
| High immature platelet fraction, % |
1.2 (0.7–1.5) | 0.7 (0.5–1.0) | 0.1–2.7 |
| Creatinine, µmol/L | 66 (60.0–78.8) | 73.5 (65.3–81.8) | 45–105 b |
Values are medians (interquartile range [IQR]) unless otherwise indicated. JAK2, Janus kinase 2; CALR, calreticulin. a According to World Health Organization; b Reference interval is combined for men and female.